IMBiologics Corp. (493280.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩13,970 (-1.48%) as of
Key statistics
- Market cap
- 206.42B
- Dividend yield
- 0.00%
- 52-week range
- 13,190.00 – 104,000.00
- Profit margin
- 0.00%
- Volume
- 105.68k
About IMBiologics Corp.
IMBiologics Corp., a biotechnology company, engages in developing immunomodulatory antibody therapeutics to treat autoimmune diseases and cancer. The company uses Optimal Antibody Modality Manufacturing Technology (IM-OpDECon) for developing differentiated treatments for autoimmune diseases and immuno-oncology based on immuno-modulatory biologics. Its products include IMB-101, a bispecific therapeutic antibody that targets OX40L and TNF to modulate pathological immune mechanisms mediating Th1/Th17 immune responses; IMB-102; IMB-201, an antibody-drug conjugate that targets HLA-G, a tumor-specific antigen; IMB-402, a concept anticancer vaccine bispecific antibody that utilizes the ePENDY (IgM-Agonist) modality to activate cancer cell-specific T cells. IMBiologics Corp. was founded in 2020 and is based in Suwon-si, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Suwon-si, South Korea
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.